Charles Schwab
TARS icon

Charles Schwab’s Tarsus Pharmaceuticals TARS Stock Holding History

Charles Schwab’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.1M Buy
335,834
+7,672
+2% +$490K ﹤0.01% 1798
2026
Q1 		$23M Sell
328,162
-4,949
-1% -$346K ﹤0.01% 1665
2025
Q4 		$27.3M Buy
333,111
+199
+0.1% +$14.9K ﹤0.01% 1554
2025
Q3 		$19.8M Buy
332,912
+3,615
+1% +$178K ﹤0.01% 1744
2025
Q2 		$13.3M Buy
329,297
+38,979
+13% +$1.75M ﹤0.01% 1875
2025
Q1 		$14.9M Sell
290,318
-3,382
-1% -$167K ﹤0.01% 1770
2024
Q4 		$16.3M Buy
293,700
+3,691
+1% +$168K ﹤0.01% 1799
2024
Q3 		$9.54M Buy
290,009
+28,130
+11% +$791K ﹤0.01% 2048
2024
Q2 		$7.12M Buy
261,879
+39,882
+18% +$1.34M ﹤0.01% 2196
2024
Q1 		$8.07M Buy
221,997
+3,335
+2% +$98.1K ﹤0.01% 2092
2023
Q4 		$4.43M Buy
218,662
+30,268
+16% +$505K ﹤0.01% 2364
2023
Q3 		$3.35M Buy
188,394
+35,730
+23% +$632K ﹤0.01% 2428
2023
Q2 		$2.76M Buy
152,664
+13,513
+10% +$215K ﹤0.01% 2454
2023
Q1 		$1.75M Buy
139,151
+600
+0.4% +$8.78K ﹤0.01% 2561
2022
Q4 		$2.03M Buy
138,551
+2,171
+2% +$35.9K ﹤0.01% 2569
2022
Q3 		$2.33M Buy
136,380
+43,647
+47% +$693K ﹤0.01% 2542
2022
Q2 		$1.35M Buy
92,733
+44,150
+91% +$663K ﹤0.01% 2688
2022
Q1 		$818K Buy
48,583
+1,402
+3% +$26K ﹤0.01% 2929
2021
Q4 		$1.06M Buy
47,181
+415
+0.9% +$10.8K ﹤0.01% 2886
2021
Q3 		$1.01M Buy
46,766
+193
+0.4% +$4.78K ﹤0.01% 2872
2021
Q2 		$1.35M Buy
46,573
+4,950
+12% +$155K ﹤0.01% 2830
2021
Q1 		$1.34M Buy
41,623
+4,400
+12% +$163K ﹤0.01% 2760
2020
Q4 		$1.54M Buy
+37,223
New +$1.06M ﹤0.01% 2667

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Charles Schwab's TARS Position: Q2 2026 in Review

Charles Schwab increased its Tarsus Pharmaceuticals (TARS) stake by 2.3% in Q2 2026, buying an estimated $490K and bringing the position to 335,834 shares worth $21.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1798.

Charles Schwab first reported a position in TARS in Q4 2020 and has held it in 23 quarters since. The position peaked at $27.3M in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Charles Schwab held 335,834 shares of Tarsus Pharmaceuticals worth $21.1M as of Q2 2026.
  • Charles Schwab bought 7,672 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $490K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1798 holding.
  • Charles Schwab first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Charles Schwab's Tarsus Pharmaceuticals position peaked at $27.3M in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.